Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Désaubry L[au]:

Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Cerezo M et al. Nat Med. (2018)

Updates in Anthracycline-Mediated Cardiotoxicity. Nebigil CG et al. Front Pharmacol. (2018)

Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes. Neal M et al. Glia. (2018)

Search results

Items: 1 to 50 of 62

1.

PHB2 (prohibitin 2) promotes PINK1-PRKN/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis.

Yan C, Gong L, Chen L, Xu M, Abou-Hamdan H, Tang M, Désaubry L, Song Z.

Autophagy. 2019 Jun 16:1-16. doi: 10.1080/15548627.2019.1628520. [Epub ahead of print]

PMID:
31177901
2.

The synthetic flavagline FL3 spares normal human skin cells from its cytotoxic effect via an activation of Bad.

Emhemmed F, Azouaou SA, Hassan S, Lefevbre R, Désaubry L, Muller CD, Fuhrmann G.

Toxicol In Vitro. 2019 Oct;60:27-35. doi: 10.1016/j.tiv.2019.04.025. Epub 2019 Apr 25.

PMID:
31028861
3.

Updates in Anthracycline-Mediated Cardiotoxicity.

Nebigil CG, Désaubry L.

Front Pharmacol. 2018 Nov 12;9:1262. doi: 10.3389/fphar.2018.01262. eCollection 2018. Review.

4.

Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.

Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C, Agoussi S, Estrada C, Adam J, Libenciuc C, Routier E, Roy S, Désaubry L, Eggermont AM, Sonenberg N, Scoazec JY, Eychène A, Vagner S, Robert C.

Nat Med. 2018 Dec;24(12):1877-1886. doi: 10.1038/s41591-018-0217-1. Epub 2018 Oct 29.

PMID:
30374200
5.

Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.

Garrido MF, Martin NJ, Bertrand M, Gaudin C, Commo F, El Kalaany N, Al Nakouzi N, Fazli L, Del Nery E, Camonis J, Perez F, Lerondel S, Le Pape A, Compagno D, Gleave M, Loriot Y, Désaubry L, Vagner S, Fizazi K, Chauchereau A.

Clin Cancer Res. 2019 Jan 15;25(2):710-723. doi: 10.1158/1078-0432.CCR-18-0704. Epub 2018 Oct 15.

PMID:
30322877
6.

Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes.

Neal M, Luo J, Harischandra DS, Gordon R, Sarkar S, Jin H, Anantharam V, Désaubry L, Kanthasamy A, Kanthasamy A.

Glia. 2018 Oct;66(10):2137-2157. doi: 10.1002/glia.23467. Epub 2018 Sep 12.

7.

The role of GPCR signaling in cardiac Epithelial to Mesenchymal Transformation (EMT).

Nebigil CG, Désaubry L.

Trends Cardiovasc Med. 2019 May;29(4):200-204. doi: 10.1016/j.tcm.2018.08.007. Epub 2018 Aug 22. Review.

PMID:
30172578
8.

Emergence of cardio-oncology.

Nebigil CG, Désaubry L.

Ann Pharm Fr. 2018 Nov;76(6):504-506. doi: 10.1016/j.pharma.2018.06.003. Epub 2018 Jul 31.

PMID:
30075937
9.

Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells.

Djehal A, Krayem M, Najem A, Hammoud H, Cresteil T, Nebigil CG, Wang D, Yu P, Bentouhami E, Ghanem GE, Désaubry L.

Eur J Med Chem. 2018 Jul 15;155:880-888. doi: 10.1016/j.ejmech.2018.06.052. Epub 2018 Jun 23.

PMID:
29960207
10.

The mTOR-S6 kinase pathway promotes stress granule assembly.

Sfakianos AP, Mellor LE, Pang YF, Kritsiligkou P, Needs H, Abou-Hamdan H, Désaubry L, Poulin GB, Ashe MP, Whitmarsh AJ.

Cell Death Differ. 2018 Nov;25(10):1766-1780. doi: 10.1038/s41418-018-0076-9. Epub 2018 Mar 9.

11.

Scalable 9-Step Synthesis of the Splicing Modulator NVS-SM2.

Abou-Hamdan H, Désaubry L.

J Org Chem. 2018 Mar 2;83(5):2954-2958. doi: 10.1021/acs.joc.7b03009. Epub 2018 Feb 13.

PMID:
29417806
12.

Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.

Yuan G, Chen X, Liu Z, Wei W, Shu Q, Abou-Hamdan H, Jiang L, Li X, Chen R, Désaubry L, Zhou F, Xie D.

J Exp Clin Cancer Res. 2018 Feb 7;37(1):21. doi: 10.1186/s13046-018-0695-5.

13.

CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts.

Tabet R, Schaeffer L, Freyermuth F, Jambeau M, Workman M, Lee CZ, Lin CC, Jiang J, Jansen-West K, Abou-Hamdan H, Désaubry L, Gendron T, Petrucelli L, Martin F, Lagier-Tourenne C.

Nat Commun. 2018 Jan 11;9(1):152. doi: 10.1038/s41467-017-02643-5.

14.

The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells ex vivo but fails to prevent leukemia development in a murine model.

Wierz M, Pierson S, Chouha N, Désaubry L, François JH, Berchem G, Paggetti J, Moussay E.

Haematologica. 2018 Apr;103(4):e154-e157. doi: 10.3324/haematol.2017.175349. Epub 2018 Jan 5. No abstract available.

15.

Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.

Yurugi H, Marini F, Weber C, David K, Zhao Q, Binder H, Désaubry L, Rajalingam K.

Oncogene. 2017 Oct 19;36(42):5914. doi: 10.1038/onc.2017.307. Epub 2017 Aug 28.

PMID:
28846116
16.

Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.

Yurugi H, Marini F, Weber C, David K, Zhao Q, Binder H, Désaubry L, Rajalingam K.

Oncogene. 2017 Aug 17;36(33):4778-4789. doi: 10.1038/onc.2017.93. Epub 2017 Apr 17. Erratum in: Oncogene. 2017 Aug 28;:.

PMID:
28414306
17.

Pro-differentiating effects of a synthetic flavagline on human teratocarcinomal cancer stem-like cells.

Emhemmed F, Ali Azouaou S, Zhao Q, Appert-Collin A, Bennasroune A, Schini-Kerth VB, Muller CD, Désaubry L, Fuhrmann G.

Cell Biol Toxicol. 2017 Jun;33(3):295-306. doi: 10.1007/s10565-016-9375-4. Epub 2016 Dec 15.

PMID:
27981389
18.
19.

Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.

Malka-Mahieu H, Newman M, Désaubry L, Robert C, Vagner S.

Clin Cancer Res. 2017 Jan 1;23(1):21-25. doi: 10.1158/1078-0432.CCR-14-2362. Epub 2016 Oct 27. Review.

20.

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.

Malka-Mahieu H, Girault I, Rubington M, Leriche M, Welsch C, Kamsu-Kom N, Zhao Q, Desaubry L, Vagner S, Robert C.

Cell Cycle. 2016 Sep 16;15(18):2405-9. doi: 10.1080/15384101.2016.1208862. Epub 2016 Aug 11.

21.

FL3, a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity.

Qureshi R, Yildirim O, Gasser A, Basmadjian C, Zhao Q, Wilmet JP, Désaubry L, Nebigil CG.

PLoS One. 2015 Nov 4;10(11):e0141826. doi: 10.1371/journal.pone.0141826. eCollection 2015.

22.

Flavaglines Ameliorate Experimental Colitis and Protect Against Intestinal Epithelial Cell Apoptosis and Mitochondrial Dysfunction.

Han J, Zhao Q, Basmadjian C, Désaubry L, Theiss AL.

Inflamm Bowel Dis. 2016 Jan;22(1):55-67. doi: 10.1097/MIB.0000000000000592.

23.

Novel carbocationic rearrangements of 1-styrylpropargyl alcohols.

Basmadjian C, Zhang F, Désaubry L.

Beilstein J Org Chem. 2015 Jun 15;11:1017-22. doi: 10.3762/bjoc.11.114. eCollection 2015.

24.

Revision of the Synthesis and Pharmacological Activity of a Reported Translation Inhibitor.

Basmadjian C, Malka-Mahieu H, Desaubry L.

Anticancer Agents Med Chem. 2015;15(10):1305-7.

PMID:
26032964
25.

Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1.

Gasser A, Brogi S, Urayama K, Nishi T, Kurose H, Tafi A, Ribeiro N, Désaubry L, Nebigil CG.

PLoS One. 2015 Apr 1;10(4):e0121027. doi: 10.1371/journal.pone.0121027. eCollection 2015.

26.

Flavaglines Stimulate Transient Receptor Potential Melastatin Type 6 (TRPM6) Channel Activity.

Blanchard MG, de Baaij JH, Verkaart SA, Lameris AL, Basmadjian C, Zhao Q, Désaubry L, Bindels RJ, Hoenderop JG.

PLoS One. 2015 Mar 16;10(3):e0119028. doi: 10.1371/journal.pone.0119028. eCollection 2015.

27.

Assessment of flavaglines as potential chikungunya virus entry inhibitors.

Wintachai P, Thuaud F, Basmadjian C, Roytrakul S, Ubol S, Désaubry L, Smith DR.

Microbiol Immunol. 2015 Mar;59(3):129-41. doi: 10.1111/1348-0421.12230.

28.

Discovery of GPCR ligands for probing signal transduction pathways.

Brogi S, Tafi A, Désaubry L, Nebigil CG.

Front Pharmacol. 2014 Nov 28;5:255. doi: 10.3389/fphar.2014.00255. eCollection 2014. Review.

29.

Search for the most 'primitive' membranes and their reinforcers: a review of the polyprenyl phosphates theory.

Nakatani Y, Ribeiro N, Streiff S, Gotoh M, Pozzi G, Désaubry L, Milon A.

Orig Life Evol Biosph. 2014 Sep;44(3):197-208. doi: 10.1007/s11084-014-9365-6. Epub 2014 Oct 30. Review.

30.

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S.

Nature. 2014 Sep 4;513(7516):105-9. doi: 10.1038/nature13572. Epub 2014 Jul 27.

PMID:
25079330
31.

Benzofuran derivatives as anticancer inhibitors of mTOR signaling.

Salomé C, Ribeiro N, Chavagnan T, Thuaud F, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry L.

Eur J Med Chem. 2014 Jun 23;81:181-91. doi: 10.1016/j.ejmech.2014.05.014. Epub 2014 May 5.

PMID:
24836070
32.

Cancer wars: natural products strike back.

Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry LG.

Front Chem. 2014 May 1;2:20. doi: 10.3389/fchem.2014.00020. eCollection 2014. Review.

33.

Selective anticancer effects of a synthetic flavagline on human Oct4-expressing cancer stem-like cells via a p38 MAPK-dependent caspase-3-dependent pathway.

Emhemmed F, Ali Azouaou S, Thuaud F, Schini-Kerth V, Désaubry L, Muller CD, Fuhrmann G.

Biochem Pharmacol. 2014 May 15;89(2):185-96. doi: 10.1016/j.bcp.2014.02.020. Epub 2014 Mar 4.

PMID:
24607276
34.

Benzofuran derivatives as a novel class of inhibitors of mTOR signaling.

Salomé C, Narbonne V, Ribeiro N, Thuaud F, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry L.

Eur J Med Chem. 2014 Mar 3;74:41-9. doi: 10.1016/j.ejmech.2013.12.020. Epub 2014 Jan 2.

PMID:
24445311
35.

Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A.

Basmadjian C, Thuaud F, Ribeiro N, Désaubry L.

Future Med Chem. 2013 Dec;5(18):2185-97. doi: 10.4155/fmc.13.177. Review.

PMID:
24261894
36.

Prohibitin ligands in cell death and survival: mode of action and therapeutic potential.

Thuaud F, Ribeiro N, Nebigil CG, Désaubry L.

Chem Biol. 2013 Mar 21;20(3):316-31. doi: 10.1016/j.chembiol.2013.02.006. Review.

37.

N-[3a-(4-Bromo-phen-yl)-8b-hy-droxy-6,8-dimeth-oxy-3-phenyl-2,3,3a,8b-tetra-hydro-1H-cyclo-penta-[b]benzofuran-1-yl]formamide monohydrate.

Aubert E, Thuaud F, Ribeiro N, Désaubry L, Espinosa E.

Acta Crystallogr Sect E Struct Rep Online. 2013 Jan 1;69(Pt 1):o52-3. doi: 10.1107/S1600536812049641. Epub 2012 Dec 8.

38.

Search for the most primitive membranes: some remaining problems.

Nakatani Y, Ribeiro N, Streiff S, Désaubry L, Ourisson G.

Orig Life Evol Biosph. 2012 Oct;42(5):497-501. doi: 10.1007/s11084-012-9313-2. Epub 2012 Oct 19. No abstract available.

PMID:
23080009
39.

Flavaglines as potent anticancer and cytoprotective agents.

Ribeiro N, Thuaud F, Bernard Y, Gaiddon C, Cresteil T, Hild A, Hirsch EC, Michel PP, Nebigil CG, Désaubry L.

J Med Chem. 2012 Nov 26;55(22):10064-73. doi: 10.1021/jm301201z. Epub 2012 Oct 23.

PMID:
23072299
40.

The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2.

Polier G, Neumann J, Thuaud F, Ribeiro N, Gelhaus C, Schmidt H, Giaisi M, Köhler R, Müller WW, Proksch P, Leippe M, Janssen O, Désaubry L, Krammer PH, Li-Weber M.

Chem Biol. 2012 Sep 21;19(9):1093-104. doi: 10.1016/j.chembiol.2012.07.012.

41.

Cytochromes P450 CYP94C1 and CYP94B3 catalyze two successive oxidation steps of plant hormone Jasmonoyl-isoleucine for catabolic turnover.

Heitz T, Widemann E, Lugan R, Miesch L, Ullmann P, Désaubry L, Holder E, Grausem B, Kandel S, Miesch M, Werck-Reichhart D, Pinot F.

J Biol Chem. 2012 Feb 24;287(9):6296-306. doi: 10.1074/jbc.M111.316364. Epub 2012 Jan 3.

42.

Recent advances in the biology and chemistry of the flavaglines.

Ribeiro N, Thuaud F, Nebigil C, Désaubry L.

Bioorg Med Chem. 2012 Mar 15;20(6):1857-64. doi: 10.1016/j.bmc.2011.10.048. Epub 2011 Oct 20. Review.

PMID:
22071525
43.

Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27.

Bernard Y, Ribeiro N, Thuaud F, Türkeri G, Dirr R, Boulberdaa M, Nebigil CG, Désaubry L.

PLoS One. 2011;6(10):e25302. doi: 10.1371/journal.pone.0025302. Epub 2011 Oct 31.

44.

Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.

Polier G, Ding J, Konkimalla BV, Eick D, Ribeiro N, Köhler R, Giaisi M, Efferth T, Desaubry L, Krammer PH, Li-Weber M.

Cell Death Dis. 2011 Jul 21;2:e182. doi: 10.1038/cddis.2011.66.

45.

Novel flavaglines displaying improved cytotoxicity.

Thuaud F, Ribeiro N, Gaiddon C, Cresteil T, Désaubry L.

J Med Chem. 2011 Jan 13;54(1):411-5. doi: 10.1021/jm101318b. Epub 2010 Dec 13.

PMID:
21142180
46.

Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.

Thuaud F, Bernard Y, Türkeri G, Dirr R, Aubert G, Cresteil T, Baguet A, Tomasetto C, Svitkin Y, Sonenberg N, Nebigil CG, Désaubry L.

J Med Chem. 2009 Aug 27;52(16):5176-87. doi: 10.1021/jm900365v.

PMID:
19655762
47.

Synthesis and biological evaluation of PEG-tirofiban conjugates.

Désaubry L, Riché S, Laeuffer P, Cazenave JP.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2028-31. doi: 10.1016/j.bmcl.2008.01.118. Epub 2008 Feb 2.

PMID:
18304813
48.

Synthesis of 3-O-methylviridicatin analogues with improved anti-TNF-alpha properties.

Ribeiro N, Tabaka H, Peluso J, Fetzer L, Nebigil C, Dumont S, Muller CD, Désaubry L.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5523-4. Epub 2007 Aug 21.

PMID:
17768048
49.

A novel type of membranes based on cholesteryl phosphate.

Sedaghat S, Désaubry L, Streiff S, Ribeiro N, Michels B, Nakatani Y, Ourisson G.

Chem Biodivers. 2004 Jan;1(1):124-8.

PMID:
17191780
50.

Concise synthesis and voltammetric studies of dielsiquinone, a cytotoxic azaanthraquinone.

Brisach-Wittmeyer A, Souna Sido AS, Guilini P, Désaubry L.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3609-10.

PMID:
15967662

Supplemental Content

Loading ...
Support Center